Healthcare Transactions and Regulatory
Haynes Boone’s Healthcare Transactions and Regulatory Practice Group helps clients navigate the highly-regulated healthcare industry while balancing the clinical and economic interests so vital to the success of our healthcare clients. Practice members have diverse backgrounds in transactional, regulatory, tax, finance, operational, clinical, litigation, and enforcement areas to offer clients services tailored to their specific needs. Our distinctive collaborative culture allows us to leverage our attorneys’ collective skills and to create innovative solutions to meet our clients’ challenges.
We regularly advise clients regarding anti-kickback, self-referral/Stark, related state laws and the mitigation of potential enforcement actions in the event of noncompliance. Our attorneys have significant experience advising clients on repayment and disclosure options and protocols, conducting internal investigations, as well as developing compliance programs. We understand the government’s renewed interest in audits and the heightened risks related to these ongoing and future initiatives. Our lawyers recognize the value of early detection and claims prevention and understand the importance of compliance programs.
We also advise on compliance with HIPAA/HITECH, licensing rules, accreditation rules and professional board rules and regulations. Our attorneys have a keen awareness and understanding of the regulatory, business planning and tax matters that are so critical to the proper structuring of a healthcare transaction. We regularly advise clients on new and existing financial relationships and entity formation, using a broad array of specialty attorneys to ensure healthcare transactions are both advantageous and legally compliant. We have experience working with a variety of individuals and entity types, including hospitals, hospice and home health companies, ambulatory surgery centers, primary care clinics, physicians and other healthcare-industry companies.
Haynes Boone Represents AdCellerant in Strategic Investment From Clearview
January 30, 2024